The Federal Circuit Court of Appeals has granted a request from Medtronic to suspend the preliminary injunction that was ordered on 11 April to limit the sale of its CoreValve system in the US.

According to the company, the injunction was previously scheduled to take effect on 23 April, and will now only occur if the appellate court rules that it was properly granted.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Last week, the Court of Appeals agreed to an expedited appeal of the injunction and the last appeal brief is due on 19 June.

Medtronic said it does not believe Edwards Lifesciences, which brought the motion for a preliminary injunction, has met the standards needed for an injunction, particularly with respect to the impact it will have on the public interest.

"We believe this ruling is good news for patients who need the CoreValve device, and our primary objective has been to work closely with physicians to ensure that their patients are able to get the therapy they need."

Medtronic senior vice-president Dr John Liddicoat said: "We believe this ruling is good news for patients who need the CoreValve device, and our primary objective has been to work closely with physicians to ensure that their patients are able to get the therapy they need."

The CoreValve system received US Food and Drug Administration (FDA) approval in January for patients at extreme risk for surgical valve replacement.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Before then, CoreValve therapy was available to extreme risk patients who were eligible to participate in the US clinical trial. The CoreValve system is not yet approved in the US for other patient groups.

Medtronic said that this ruling has no impact on the sale or marketing of CoreValve outside of the US or the use of CoreValve in the current US clinical trials.

In March, data presented at the American College of Cardiology (ACC) annual meeting and simultaneously published in The New England Journal of Medicine showed superior results compared with surgical aortic valve replacement (SAVR) at one year in patients at increased risk for surgery.

It is claimed to be the first prospective and randomised study to show any transcatheter aortic valve to be superior to surgery. Medtronic anticipates FDA approval of the CoreValve system for high risk patients sometime this summer.

Medical Device Network Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Medical Device Network Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now